Investors Alert: Lead Plaintiff Deadline Approaches for Applied Therapeutics Lawsuit
In a vital notice for shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT), The Gross Law Firm has reminded investors of an impending lead plaintiff deadline associated with the ongoing litigation involving the biopharmaceutical company. Shareholders who acquired shares during the specified class period from January 3, 2024, to December 2, 2024, are encouraged to act swiftly to secure their participation in this class action lawsuit.
This legal action derives from serious allegations against Applied Therapeutics, which surfaced after unsettling news agitated the market. On November 27, 2024, the company revealed it received a Complete Response Letter (CRL) from the FDA concerning its New Drug Application (NDA) for govorestat, its leading drug candidate. The CRL pointed to notable deficiencies in the clinical application, concluding that the FDA could not approve the NDA in its current state. The fallout from this announcement was immediately felt in the stock price, which plummeted from a closing value of $10.21 on November 26, 2024, to $8.57 the following day. This descent continued, culminating in a staggering drop of more than 80% in a matter of days.
As if this news weren’t damaging enough, Applied Therapeutics shared further distressing information on December 2, 2024, regarding a "warning letter" it received from the FDA about the clinical trial issues that contributed to the CRL. This revelation continued to hammer the stock, pushing it down to as low as $1.29 per share by December 5, 2024.
For shareholders, the stakes in this class action are significantly high. Participating in the class action, and potentially being appointed as a lead plaintiff, may offer shareholders a path to recover some of their losses incurred due to the drastic decrease in stock value following these disclosures. It is paramount for those affected to register before the critical deadline of February 18, 2025, to be included in this collective movement.
Shareholders do not need to take on financial burdens or navigate this complex legal avenue alone. By registering with The Gross Law Firm, investors will be enrolled in a portfolio monitoring service that provides ongoing updates about their involvement. This is a no-cost opportunity for those invested in Applied Therapeutics.
Investors looking to protect their rights and possibly recover losses from their investments in Applied Therapeutics are urged to contact the Gross Law Firm promptly. Interested shareholders can find more details and register online to ensure that their voices are heard in this monumental case. Given the serious allegations and the sharp decline in stock value, time is of the essence.
The Gross Law Firm is a well-regarded national entity specializing in class action lawsuits, dedicated to upholding the rights of investors affected by corporate malfeasance. Their commitment to ensuring corporate accountability means that they seek justice for those who have suffered due to misinformation or fraudulent practices.
For more information or to initiate your claim, contact The Gross Law Firm at:
Do not delay in securing your place in this class action. The deadline looms, and every day counts in pursuing potential recovery from your investment losses. Act today to ensure you are part of this significant legal action involving Applied Therapeutics, Inc.
Background of the Case
This legal action derives from serious allegations against Applied Therapeutics, which surfaced after unsettling news agitated the market. On November 27, 2024, the company revealed it received a Complete Response Letter (CRL) from the FDA concerning its New Drug Application (NDA) for govorestat, its leading drug candidate. The CRL pointed to notable deficiencies in the clinical application, concluding that the FDA could not approve the NDA in its current state. The fallout from this announcement was immediately felt in the stock price, which plummeted from a closing value of $10.21 on November 26, 2024, to $8.57 the following day. This descent continued, culminating in a staggering drop of more than 80% in a matter of days.
As if this news weren’t damaging enough, Applied Therapeutics shared further distressing information on December 2, 2024, regarding a "warning letter" it received from the FDA about the clinical trial issues that contributed to the CRL. This revelation continued to hammer the stock, pushing it down to as low as $1.29 per share by December 5, 2024.
Why This Matters
For shareholders, the stakes in this class action are significantly high. Participating in the class action, and potentially being appointed as a lead plaintiff, may offer shareholders a path to recover some of their losses incurred due to the drastic decrease in stock value following these disclosures. It is paramount for those affected to register before the critical deadline of February 18, 2025, to be included in this collective movement.
Shareholders do not need to take on financial burdens or navigate this complex legal avenue alone. By registering with The Gross Law Firm, investors will be enrolled in a portfolio monitoring service that provides ongoing updates about their involvement. This is a no-cost opportunity for those invested in Applied Therapeutics.
Call to Action
Investors looking to protect their rights and possibly recover losses from their investments in Applied Therapeutics are urged to contact the Gross Law Firm promptly. Interested shareholders can find more details and register online to ensure that their voices are heard in this monumental case. Given the serious allegations and the sharp decline in stock value, time is of the essence.
The Gross Law Firm is a well-regarded national entity specializing in class action lawsuits, dedicated to upholding the rights of investors affected by corporate malfeasance. Their commitment to ensuring corporate accountability means that they seek justice for those who have suffered due to misinformation or fraudulent practices.
For more information or to initiate your claim, contact The Gross Law Firm at:
- - Phone: (646) 453-8903
- - Email: [email protected]
- - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
Do not delay in securing your place in this class action. The deadline looms, and every day counts in pursuing potential recovery from your investment losses. Act today to ensure you are part of this significant legal action involving Applied Therapeutics, Inc.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.